Hoerni B, Durand M, Richaud P, De Mascarel A, Hoerni-Simon G, Chauvergne J, Lagarde C
Br J Haematol. 1979 Aug;42(4):507-14. doi: 10.1111/j.1365-2141.1979.tb01163.x.
Forty-eight patients less than 65 years old, suffering non-Hodgkin's malignant lymphomas with one or more criteria of poor prognosis, were priorly placed in complete remission by an association of chemo + radio + chemotherapy. They were then randomized to receive either BCG in weekly scarifications for 3 years or no further treatment. Five patients were excluded (four after pathological reassessment); 43 are thus evaluable. There were 13 relapses out of 23 control patients and three relapses out of 20 treated patients (0.01 less than P less than 0.025). This difference is more distinct for clinical stages I and II (0.01 less than P less than 0.025) than for stages III and IV (not significant). Eight patients died in the control group whereas there was only one death in the treated group (0.025 less than P less than 0.05). These results indicate than BCG is useful in maintaining remission in about 40% of the cases and also in increasing their survival, especially in patients with clinical stages I or II.
48例年龄小于65岁、患有非霍奇金恶性淋巴瘤且具有一项或多项预后不良标准的患者，先前通过化疗+放疗+化疗联合治疗达到完全缓解。然后将他们随机分为两组，一组接受为期3年的每周划痕接种卡介苗治疗，另一组不再接受进一步治疗。5例患者被排除（4例经病理重新评估后排除）；因此可评估的患者有43例。23例对照组患者中有13例复发，20例治疗组患者中有3例复发（0.01＜P＜0.025）。这种差异在临床I期和II期（0.01＜P＜0.025）比在III期和IV期更明显（无显著性差异）。对照组有8例患者死亡，而治疗组仅有1例死亡（0.025＜P＜0.05）。这些结果表明，卡介苗在约40%的病例中有助于维持缓解，并且还能提高患者的生存率，尤其是临床I期或II期的患者。
